Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.

Journal of medicinal chemistry·2026
Same author

Partial Phase Remixing of Segregated Mixed Halide Perovskite Nanocrystals Induced by an Instant Change in an External Electric Field.

The journal of physical chemistry letters·2026
Same author

A rapid semi-automated trajectory planning method for non-coplanar interstitial brachytherapy in cervical cancer using a greedy algorithm.

Radiation oncology (London, England)·2026
Same author

Loss of Arginase 2 Promotes Lung Metastasis in immune-competent hosts via Nitric Oxide Synthase 2-Dependent Th17 Response.

bioRxiv : the preprint server for biology·2026
Same author

Formation of Abundant Quantum Emitters in 2D Lead-Halide Perovskites.

Nano letters·2026
Same author

Corrigendum to "Water-induced directed self-assembly of matrine-unsaturated fatty acid natural deep eutectic solvent into eutectogel for anti-photoaging" [J. Colloid Interface Sci. 719 (2026) 140622].

Journal of colloid and interface science·2026

Related Experiment Video

Updated: Jun 12, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Fresh platinum complexes with promising antitumor activity.

Xiaoyong Wang1

  • 1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, P.R. China. boxwxy@nju.edu.cn

Anti-Cancer Agents in Medicinal Chemistry
|June 16, 2010
PubMed
Summary

Novel platinum complexes offer improved cancer treatment by overcoming drug resistance and reducing toxicity. Structural modifications enhance DNA damage modes, leading to better antitumor efficacy than traditional platinum drugs.

More Related Videos

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Molecular Biology

Background:

  • Platinum-based chemotherapy is a primary treatment for solid tumors.
  • Current platinum drugs like cisplatin face challenges including drug resistance and systemic toxicity.
  • Minimizing side effects of platinum drugs is a significant clinical goal.

Purpose of the Study:

  • To review recent advancements in novel platinum complexes developed in the last five years.
  • To highlight platinum complexes with DNA damage mechanisms distinct from cisplatin.
  • To explore strategies for overcoming cisplatin resistance and improving antitumor efficacy.

Main Methods:

  • Literature review of novel platinum complexes from the past five years.
  • Categorization of complexes: cisplatin/oxaliplatin analogues, monofunctional Pt(II), polynuclear Pt(II), trans-Pt(II), and Pt(IV) complexes.
  • Analysis of reported antitumor activities and resistance circumvention potential.

Main Results:

  • Diverse platinum complexes, including analogues, monofunctional, polynuclear, trans, and Pt(IV) types, exhibit significant antitumor activity.
  • Several novel complexes demonstrate potential in overcoming cisplatin resistance.
  • Structural modifications demonstrably alter DNA binding modes and damage processes.

Conclusions:

  • Structural modifications of platinum complexes can significantly alter their DNA interaction and damage mechanisms.
  • These modifications offer a promising avenue for enhancing antitumor efficacy and overcoming resistance to existing platinum drugs.
  • Novel platinum complexes represent a valuable frontier in cancer chemotherapy development.